Date: 2012-02-20
Type of information: Development agreement
Compound: diagnostic test for an Amgen cancer drug candidate in clinical development
Company: Dako (Denmark) Amgen (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
Disease: undisclosed cancer
Details: Dako has entered into a new collaboration agreement with Amgen on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development. In January 2012, Dako has already announced a collaboration agreement with Amgen introducing a new business model which supports the concurrent development of drug and diagnostics for a rare but deadly cancer – something that up to this point has been difficult to achieve in the industry.
Financial terms:
Latest news:
